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At the end of 2007, 33.2 million people including 2.5 mil-
lion children were living with HIV; > 85% of HIV-infected
children were in Africa. At the end of 2006, 115 000 chil-
dren were on HAART, a global coverage rate of 15% with
sub-Saharan Africa having the lowest regional coverage.
HIV affects the immature brain causing static or progres-
sive encephalopathy (PE). PE is characterized by acquired
microcephaly, failure to attain or loss of neurodevelop-
mental milestones, or loss of intellectual ability, and
acquired symmetric motor defects. Isolated neurodevel-
opmental delays and peripheral nervous system disease
occur as a direct consequence of HIV infection. Suscepti-
bility to opportunistic infection (OI), due to systemic
immunodeficiency, predisposes HIV-infected children to
CNS infections including acute bacterial and tuberculous
meningitis, CMV co-infection, EBV-associated primary
lymphoma and in older children cryptococcal meningitis.
HAART may induce an immune reconstitution inflamma-
tory response to several microorganisms including myco-
bacterium tuberculosis and JC virus, causing CNS
deterioration. Neurological manifestations occur in 20–
80% of HIV-infected children. Complex clinical presenta-
tions may be difficult to classify with the layering effect of
multiple pathologies. There are limited descriptive studies
from resource-constrained countries. In one hospital-
based, cross-sectional survey (n = 80, median age = 5.2
years), 60% had a variety of neurological and neurodevel-
opmental deficits.
The neuropathogenesis of HIV encephalopathy is incom-
pletely understood. Several pathogenic events are
involved including (1) CNS invasion following receptor/
co-receptor-mediated HIV infection of monocytes/macro-
phages and CD4+ T-lymphocytes, (2) promotion of HIV-
infected PBMC trafficking across the BBB by astrocytes
and microglia (Trojan-horse effect), (3) neurotoxin elabo-
ration induced by viral factors and inflammatory media-
tors, (4) CD4-independent astrocyte invasion by HIV, (4)
neuronal death mediated through viral-induced chemok-
ine receptor expression, and microglial/macrophage-
dependent and microglial-independent apoptotic death,
and (5) inhibition of neural stem cell proliferation by
viral gp120. Both direct and indirect mechanisms are
involved in neuronal injury and death.
Early initiation of HAART during infancy prevents the
development of HIV encephalopathy, lowering the preva-
lence of progressive encephalopathy to < 2%. HAART
reverses existing neurological abnormalities, although not
completely, resulting in residual motor and cognitive
sequelae (arrested PE) and consequent scholastic impair-
ments. HAART also reduces the frequency of OIs and
malignancy.
In conclusion, HIV-associated nervous system disease
remains highly prevalent in settings where treatment is
sub-optimal. Implementation of HAART during infancy
and additional prophylaxis against OIs such as pneumo-
coccal vaccination lowers the risk significantly.
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